HCW Biologics is trading 10.8% down at $3.21 as the stock undergoes consolidation and profit-taking following a sharp multi-session rally.
- The recent surge was fueled by significant insider participation, including a $1.6 million private placement and direct share purchases around July 29, 2026.
- Today’s decline occurs despite the broader biotech sector trading higher, with no new negative company-specific news reported to justify the pullback.